Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Millennium Management LLC decreased its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 55.8% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 146,517 shares of the biotechnology company’s stock after selling 185,049 shares during the period. Millennium Management LLC owned 0.48% of AnaptysBio worth $1,940,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ANAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of AnaptysBio by 21.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,012 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 2,701 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in AnaptysBio by 85.3% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 85,381 shares of the biotechnology company’s stock worth $1,130,000 after purchasing an additional 39,307 shares in the last quarter. Graham Capital Management L.P. bought a new position in AnaptysBio in the 4th quarter valued at $251,000. Granahan Investment Management LLC purchased a new position in shares of AnaptysBio during the 4th quarter valued at $1,404,000. Finally, Ensign Peak Advisors Inc increased its holdings in shares of AnaptysBio by 184.4% in the fourth quarter. Ensign Peak Advisors Inc now owns 215,454 shares of the biotechnology company’s stock worth $2,853,000 after purchasing an additional 139,699 shares during the period.

AnaptysBio Stock Down 1.7%

AnaptysBio stock opened at $21.86 on Tuesday. The firm has a fifty day simple moving average of $19.80 and a two-hundred day simple moving average of $18.25. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31. The company has a market capitalization of $642.25 million, a PE ratio of -3.60 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.02. The company had revenue of $27.77 million during the quarter, compared to analysts’ expectations of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase program on Monday, March 24th that permits the company to repurchase $75.00 million in outstanding shares. This repurchase authorization permits the biotechnology company to repurchase up to 13.1% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

ANAB has been the subject of several recent analyst reports. Wolfe Research assumed coverage on AnaptysBio in a research report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 target price for the company. HC Wainwright reissued a “neutral” rating and set a $22.00 price objective on shares of AnaptysBio in a report on Tuesday, March 4th. Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Wells Fargo & Company lifted their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price target on shares of AnaptysBio in a report on Thursday, May 29th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.38.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.